I think she was venting her frustration, rather than taking the mickey.
But the complainers are having some effect. The chairman's statement at the AGM on irinotecan was much improved, and reads as
"The final stages of preclinical work for the DEP® irinotecan phase 1 / 2 trial are almost complete and the trial is planned to commence this financial year."
whereas in the annual report it read as
"We plan to advance our third DEP® oncology product, DEP® irinotecan, into the clinic around the end of the year."
Less ambiguity and vagueness I think. Keep it up Rob! If and when SPL is to join the ASX200 you would never get away with your annual report wording. Too many new analysts would pull you up on it.
SPL Price at posting:
$1.45 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)